Literature DB >> 9263528

A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.

A Miyauchi1, S Egawa, H Futami, K Kuma, T Obara, K Yamaguchi.   

Abstract

In individuals who carry germline mutations in tumor suppressor genes predisposing them to inherited cancer syndromes, occurrence of somatic mutations in the same genes contributes to tumorigenesis. Germline mutations in the RET proto-oncogene predispose individuals to multiple endocrine neoplasia (MEN) type 2 syndromes. Since these mutations are oncogenic by themselves, somatic mutations in the same gene had been thought unnecessary. Recently, a somatic mutation at codon 918 of RET was reported in medullary thyroid carcinoma (MTC) and C-cell hyperplasia in patients with MEN 2A or familial MTC (FMTC), suggesting its possible contribution to tumorigenesis. We describe here a novel somatic mutation at codon 919 in a patient with FMTC carrying a germline mutation at codon 768 that may also be related to tumor progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263528      PMCID: PMC5921476          DOI: 10.1111/j.1349-7006.1997.tb00414.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  15 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

3.  Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

Authors:  D J Marsh; S D Andrew; C Eng; D L Learoyd; A G Capes; R Pojer; A L Richardson; C Houghton; L M Mulligan; B A Ponder; B G Robinson
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

4.  DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene.

Authors:  I Ceccherini; R M Hofstra; Y Luo; R P Stulp; V Barone; T Stelwagen; R Bocciardi; H Nijveen; A Bolino; M Seri
Journal:  Oncogene       Date:  1994-10       Impact factor: 9.867

5.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

6.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Authors:  M Santoro; F Carlomagno; A Romano; D P Bottaro; N A Dathan; M Grieco; A Fusco; G Vecchio; B Matoskova; M H Kraus
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

7.  Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland.

Authors:  S A Wells; S B Baylin; W M Linehan; R E Farrell; E B Cox; C W Cooper
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

8.  Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.

Authors:  N Asai; T Iwashita; M Matsuyama; M Takahashi
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity.

Authors:  J R Farndon; G S Leight; W G Dilley; S B Baylin; R C Smallridge; T S Harrison; S A Wells
Journal:  Br J Surg       Date:  1986-04       Impact factor: 6.939

10.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

Authors:  K M Carlson; S Dou; D Chi; N Scavarda; K Toshima; C E Jackson; S A Wells; P J Goodfellow; H Donis-Keller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

View more
  6 in total

1.  Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

Authors:  O Gimm; D J Marsh
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 2.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.

Authors:  S Jindrichova; R Kodet; L Krskova; P Vlcek; B Bendlova
Journal:  J Mol Med (Berl)       Date:  2003-11-15       Impact factor: 4.599

4.  Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.

Authors:  Christian A Koch; Frederieke M Brouwers; Alexander O Vortmeyer; Andrea Tannapfel; Steven K Libutti; Zhengping Zhuang; Karel Pacak; Hartmut P H Neumann; Ralf Paschke
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

5.  Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.

Authors:  A Miyauchi; H Futami; N Hai; T Yokozawa; K Kuma; N Aoki; S Kosugi; K Sugano; K Yamaguchi
Journal:  Jpn J Cancer Res       Date:  1999-01

6.  Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.

Authors:  S Uchino; S Noguchi; M Adachi; M Sato; H Yamashita; S Watanabe; T Murakami; M Toda; N Murakami; H Yamashita
Journal:  Jpn J Cancer Res       Date:  1998-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.